Brain, Obesity, Dopamine and You Study
NCT01094756 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82
Last updated 2016-11-02
Summary
Central dopamine is thought to play a significant role in obesity. In support of this idea, animal studies and one human positron emission tomography (PET) study have found reduced postsynaptic D2-like receptor availability in the striatum in obesity, with lower D2 receptor availability associated with higher weight. In addition, reward sensitivity and hedonic responses, known to be related to dopamine function, have also been implicated in obesity and obesity-related eating behavior. These reports have led to the concept that dopaminergic abnormalities (e.g. reduced D2-like receptors) influence reward sensitivity, leading to altered eating behaviors and eventually obesity. However, there are several critical limitations of the human D2 receptor studies that limit the strength of their conclusions and thus the interpretations and speculations embedded in literature that relies on this work. First, estimates of D2-like receptors in humans have been confounded by potential differences in endogenous dopamine release since the PET ligand (raclopride) used is known to be displaceable from receptors by endogenous dopamine. Second, failure to rigorously screen obese individuals for diabetes confounds conclusions, since diabetes has been independently associated with dopaminergic abnormalities such as reduced D2-like receptors and muted dopamine release in diabetic rats. Finally, no human studies have addressed whether reduced D2-like receptor levels are a risk factor for obesity, a consequence of engaging in obesity-related behaviors or being obese or all of the above.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
meal replacements, psychotherapy, dietary education
After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Tamara Hershey, Ph.D. · Washington University School of Medicine
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-07-31
- Primary Completion
- 2015-06-30
- Completion
- 2016-10-31
Countries
- United States
Study Locations
More Related Trials
-
Effect of mCPP on Cognitive Control, Appetite, and Neural Responses
NCT03962829 ·Status: TERMINATED ·Phase: NA
-
Weight Management Program for Patients With First Episode Psychosis
NCT05207982 ·Status: COMPLETED ·Phase: PHASE1
-
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT05405244 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Apathy in Glycemic Control
NCT00844090 ·Status: COMPLETED ·Phase: NA
-
Effects of Ghrelin Administration on Dopamine and Effort
NCT05318924 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
NCT00339014 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 ·Status: COMPLETED ·Phase: PHASE4
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Bromocriptine and Insulin Sensitivity
NCT02428946 ·Status: COMPLETED ·Phase: NA
-
Dopamine and Insulin in Psychosis
NCT07252752 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Effect of Obesity in Dexmedetomidine Metabolic Clearance
NCT02557867 ·Status: UNKNOWN ·Phase: PHASE4
-
Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.
NCT00759993 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of LDX on Cognitive Processes and Appetite
NCT04181957 ·Status: TERMINATED ·Phase: NA
-
The Effect of PinnoThin on Satiety and Food Intake
NCT01034605 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
NCT01281228 ·Status: COMPLETED ·Phase: NA
-
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT05744479 ·Status: RECRUITING ·Phase: PHASE4
-
The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety
NCT00328913 ·Status: COMPLETED ·Phase: PHASE2
-
Metformin for Weight Loss in Schizophrenia
NCT01177709 ·Status: TERMINATED ·Phase: NA
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
NCT01052714 ·Status: COMPLETED ·Phase: NA
-
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
NCT00819234 ·Status: COMPLETED ·Phase: PHASE2
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 ·Status: COMPLETED ·Phase: NA
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
NCT00625170 ·Status: COMPLETED ·Phase: NA
-
Anti-psychotic Medication (Stable Dose) Weight Loss Study
NCT01272765 ·Status: WITHDRAWN ·Phase: PHASE2
-
Northern Manhattan Study of Metabolism and Mind
NCT02470260 ·Status: ACTIVE_NOT_RECRUITING
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
NCT00625014 ·Status: COMPLETED ·Phase: NA